- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 23.03. | FDA approves Cidara's Rezzayo as antifungal treatment for candidemia and invasive candidiasis | ||
| 23.03. | Ex-Seagen CEO Clay Siegall emerges as CEO of private biotech | ||
| 23.03. | Sanofi, Regeneron boast PhIII win with Dupixent in COPD, clearing first bar for expansion | ||
| 23.03. | Genentech to stop commercial manufacturing at California headquarters | ||
| 22.03. | FDA advisors unanimously recommend accelerated approval for Biogen's ALS drug | ||
| 22.03. | Incyte wins accelerated approval for PD-1 in rare skin cancer | ||
| 22.03. | Federal judge denies Amgen's motion to dismiss Regeneron antitrust case | ||
| 22.03. | Regeneron scores label expansion for cholesterol drug Evkeeza | ||
| 22.03. | Social media patient influencers 'dancing in the gray' of pharma marketing, more clarity needed, researcher says | ||
| 22.03. | Moderna CEO defends Covid-19 vaccine price change at Senate committee grilling | ||
| 22.03. | FDA rejects AbbVie's infusion therapy for Parkinson's, requests more info on pump device | ||
| 22.03. | Biohaven grabs TYK2/JAK1 drug for $20M to start, $950M on the line - to go after Parkinson's | ||
| 22.03. | Quince Therapeutics faces takeover bid from shareholder Echo Lake Capital | ||
| 22.03. | Astellas fleshes out more PhIII data for Claudin 18.2 drug | ||
| 22.03. | In insulin resistance pact, Dewpoint adds Novo Nordisk to its pharma-rich pipeline | ||
| 22.03. | Novartis touts seven years of durability data for Zolgensma | ||
| 22.03. | 'Banding together': 50 female biotech executives lay out plans for board diversity, new companies and mentoring founders | ||
| 22.03. | The venture crew at Mubadala are upping their biotech creation game, taking careful aim at a new frontier in drug development | ||
| 22.03. | Roche and Lilly team up to develop blood test to detect early signs of Alzheimer's | ||
| 22.03. | 89bio's PhII data add to quick succession of NASH readouts as field seeks turnaround | ||
| 22.03. | A $123M Flare will get Third Rock oncology biotech into the clinic this year | ||
| 22.03. | After getting his drug back, Landos founder assembles new startup for the big PhIII test | ||
| 21.03. | NIH rejects another attempt to 'march-in' on prostate cancer drug over excessive price | ||
| 21.03. | FDA warns Procter & Gamble over NyQuil label's ingredient listings | ||
| 21.03. | FTC says patent battle over Parkinson's drug could have 'significant implications' for patients |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
